

Company Focus

19 November 2007 | 15 pages

Everest Kanto Cylinder (EKCL.B0)

Target price change


✓ Estimate change 🗹

Buy: Resuming Coverage; Increasing Target Price to Rs437

- Raising TP to Rs437 We resume coverage on EKC and increase our target price to Rs437 (Rs260 earlier) on the back of material new expansion plans announced over the last few months and capital raised to part-fund the same.
- Well-timed expansions positive and fully funded Besides the Dubai expansion (recently commenced) and China greenfield plant (to start next Q), EKC plans to: (1) expand the Gandhidham facility (0.2m industrial cyl/yr), (2) set up a greenfield plant at Kandla SEZ (0.3m CNG cyl/yr), and de-bottleneck Tarapur. Total capex envisaged is c.US\$50m. The company has recently raised ~US\$57m through an FCCB and private placement. We view the expansions as positive as they diversify two key risks – RM supplies and the China market.
- Significant boost to earnings The new expansions are targeted at meeting the burgeoning domestic and global demand for CNG applications as well as producing value-added products such as jumbo cylinders which would add meaningfully to margins and, more importantly, address competitive pressures. Total capacity to grow 3x in 4-5 yrs from 0.8m/yr currently. We correspondingly adjust FY08E earnings by 3% and significantly revise FY09-10E by 18-33%.
- Reiterate Buy (1M) Our new Rs437 TP implies 40% upside from current levels and is based on 22x Sep-09E earnings, well supported by 47% EPS CAGR over FY07-10E. EKC is well positioned to benefit from the rapidly growing global CNG market and is, in our view, one of the most leveraged plays to the expanding city gas distribution market in India.

Buy/Medium Risk	1 M
Price (16 Nov 07)	Rs311.50
Target price	Rs437.00
from Rs260.00	
Expected share price return	40.3%
Expected dividend yield	0.5%
Expected total return	40.8%
Market Cap	Rs30,405M US\$778M

Pric	e Periormance	(KIG: ENGL.BU,	BB: ENGL IN)
INR			



Statistical Abstract

Source: Powered by dataCentral

Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield
31 Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2006A	324	3.68	54.6	84.7	18.2	33.7	0.2
2007A	718	7.35	99.9	42.4	10.1	31.7	0.3
2008E	1,115	10.54	43.4	29.5	6.5	28.4	0.5
2009E	1,729	16.35	55.1	19.1	5.0	31.2	0.8
2010E	2,469	23.34	42.8	13.3	3.8	34.1	1.4

Rahul Singh¹ +91-22-6631-9863

rahul.r.singh@citi.com

Saurabh Handa¹ +91-22-6631-9858 saurabh.handa@citi.com

Garima Mishra¹ garima.mishra@citi.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. ¹Citigroup Global Markets India Private Limited

EV/EBITDA adjusted (x) 52.4 27.0 19.2 12.6 9.1	Fiscal year end 31-Mar	2006	2007	2008E	2009E	2010E
EV/EB/TDA adjusted (x) 52.4 27.0 19.2 12.6 9.1 P/BV (x) 18.2 10.1 6.5 5.0 3.8 Per Share Data (Rs) EPS adjusted 3.68 7.35 10.54 16.35 23.34 EPS reported 3.68 7.35 10.54 16.35 23.34 EPS adjusted 3.68 7.35 10.54 16.35 23.34 EVPS 17.13 30.98 47.75 61.84 81.11 DPS 0.70 1.00 1.65 2.56 4.35 Profit & Loss (RsM) Net sales 2.355 3.851 5.793 8.953 12.463 Operating expenses -1,865 -2.884 -4.395 -6.763 -9.38 EBIT 490 967 1.398 2.191 3.125 EBIT 490 967 1.398 2.191 3.125 EBIT 476 953 1.411 2.135 3.011 Tax -141 -236 -296 -406 -544 Extraord./Min.Int./Pref.div. -11 0 0 0 0 Caption 0 0 0	Valuation Ratios					
P/BV (c) 18.2 10.1 6.5 5.0 3.8	P/E adjusted (x)	84.7	42.4	29.5		13.3
Dividend yield (%) 0.2 0.3 0.5 0.8 1.4						9.1
Per Share Data (Rs) EPS dijusted 3.68 7.35 10.54 16.35 23.34 EPS reported 3.68 7.35 10.54 16.35 23.34 BVPS 17.13 30.98 47.75 61.84 81.11 DPS 0.70 1.00 1.65 2.56 4.35 Profit & Loss (RsM) Net sales 2,355 3.851 5.793 8.953 12.463 Operating expenses -1.865 -2,884 4.395 -6,763 -9,338 EBIT 490 967 1,398 2,191 3,125 Not interest expense -37 -53 -102 -164 -198 Non-operating/exceptionals 22 40 115 108 84 Pre-tax profit 476 953 1,411 2,135 3,011 Tax -141 -236 -296 -406 -542 Extraord/Min.Int./Pref.div. -11 0 0 0 0 <td>* *</td> <td></td> <td></td> <td></td> <td></td> <td>3.8</td>	* *					3.8
EPS adjusted 3.68 7.35 10.54 16.35 23.34 EPS reported 3.68 7.35 10.54 16.35 23.34 BVPS 17.13 30.98 47.75 61.84 81.11 DPS 0.70 1.00 1.65 2.56 4.33 Profit & Loss (RsM) Net sales 2,355 3.851 5,793 8,953 12,463 Operating expenses -1,865 -2,884 -4,395 -6,763 -9,38 EBIT 490 967 1,398 -6,763 -9,38 EBIT operating expenses -37 -53 -102 -164 -198 Non-operating/exceptionals 22 40 115 108 88 Pre-tax profit 476 953 1,411 2,135 3,011 Tax -141 -236 -296 -406 -542 Extraord/Minint/Pref.div. -11 0 0 0 0 Extraord/Minint Ref.div.		0.2	0.3	0.5	0.8	1.4
EPS reported 3.68 7.35 10.54 16.35 23.34						
BVPS						23.34
DPS						
Profit & Loss (RSM)						
Net sales		0.70	1.00	1.00	2.56	4.39
Operating expenses -1,865 -2,884 -4,395 -6,763 -9,338 EBIT 490 967 1,398 2,191 3,128 Non-operating/exceptionals 22 40 115 108 84 Pre-tax profit 476 953 1,411 2,135 3,011 Tax -141 -236 -296 -406 -542 Extraord/Min.Int/Pref.div. -11 0 0 0 0 Reported net income 324 718 1,115 1,729 2,465 Adjusted earnings 324 718 1,115 1,729 2,465 Adjusted EBITDA 588 1,145 1,646 2,605 3,655 Growth Rates (%) Sales 77.9 63.5 50.4 54.6 39.2 Sales 77.9 63.5 50.4 54.6 39.2 EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITOA adjusted 104.2 94.7 <td>• •</td> <td>0.055</td> <td>2.051</td> <td>F 700</td> <td>0.050</td> <td>10.400</td>	• •	0.055	2.051	F 700	0.050	10.400
Refired Embedding						
Net interest expense -37 -53 -102 -164 -198						
Non-operating/exceptionals 22 40 115 108 84 Pre-tax profit 476 953 1,411 2,135 3,011 Tax						
Pre-tax profit 476 953 1,411 2,135 3,011 Tax -141 -236 -296 -406 -542 Extraord./Min.Int./Pref.div. -11 0 0 0 0 Reported net income 324 718 1,115 1,729 2,468 Adjusted earnings 324 718 1,115 1,729 2,469 Adjusted EBITDA 588 1,145 1,646 2,605 3,655 Growth Rates (%) 581 1,145 1,646 2,605 3,655 Growth Rates (%) 582 43.5 50.4 54.6 39.2 EBIT Adjusted 133.9 97.2 44.6 56.7 42.8 EBIT Adjusted 104.2 94.7 43.8 58.2 40.3 EBIT Adjusted 104.2 94.7 43.8 58.2 40.3 EBIT Adjusted 104.2 94.7 43.8 58.2 40.3 EBIT Adjusted 104.2 94.7 43.8						84
Tax						3,011
Reported net income 324 718 1,115 1,729 2,469 Adjusted earnings 324 718 1,115 1,729 2,469 Adjusted EBITDA 588 1,145 1,646 2,605 3,655 Growth Rates (%) 588 1,145 1,646 2,605 3,655 Sales 77.9 63.5 50.4 54.6 39.2 EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITDA adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 EBIT Adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 EBIT Adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 300 -182 679 881 1,722 Cash Erlow (RsM) 112 -1,078 -684 <td>Tax</td> <td>-141</td> <td>-236</td> <td>-296</td> <td>-406</td> <td>-542</td>	Tax	-141	-236	-296	-406	-542
Adjusted earnings 324 718 1,115 1,729 2,469 Adjusted EBITDA 588 1,145 1,646 2,605 3,655 Growth Rates (%) Sales 77.9 63.5 50.4 54.6 39.2 EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITDA adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525	Extraord./Min.Int./Pref.div.			-	-	0
Adjusted EBITDA 588 1,145 1,646 2,605 3,655 Growth Rates (%) Sales 77.9 63.5 50.4 54.6 39.2 EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITDA adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722						2,469
Sales 77.9 63.5 50.4 54.6 39.2					,	2,469
Sales 77.9 63.5 50.4 54.6 39.2 EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITDA adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 37		588	1,145	1,646	2,605	3,655
EBIT adjusted 133.9 97.2 44.6 56.7 42.6 EBITDA adjusted 104.2 94.7 43.8 58.2 40.3 EPS adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 Capital expenditure -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -1,261 Capital expenditure -591 -717 -2,561 -1,412 Capital expend						
EBITDA adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Accounts receivable 234 575 878 1,357 1,885 Accounts payable 266 379 578 893 1,244 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0 Cash B. 205 Cash Flow (RsM)						39.2
EPS adjusted 54.6 99.9 43.4 55.1 42.8 Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) 8,878 11,377 14,011 1,554 1,261 1,845						
Cash Flow (RsM) Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) 7 114 -196 -303 -520 Change in cash 2,514 4,718 8,878 11,377 14,011 Cash &						
Operating cash flow 300 -182 679 881 1,722 Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) 1 1,083 -293 584 Balance Sheet (RsM) 2 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 <td< td=""><td></td><td>J4.0</td><td>33.3</td><td>40.4</td><td>33.1</td><td>42.0</td></td<>		J4.0	33.3	40.4	33.1	42.0
Depreciation/amortization 98 178 248 414 530 Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RSM)		300	-187	679	881	1 722
Net working capital -122 -1,078 -684 -1,262 -1,278 Investing cash flow -591 -717 -2,561 -1,412 -612 Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,889 Net fixed assets 939 1,478 3,792 4,790 4,871 <						
Investing cash flow						
Capital expenditure -591 -717 -2,561 -1,412 -612 Acquisitions/disposals 0 0 0 0 0 0 Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) 50 192 1,083 -293 584 Balance Sheet (RsM) 50 192 1,083 -293 584 Balance Sheet (RsM) 50 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,889 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004						-612
Financing cash flow 667 1,091 2,965 238 -525 Borrowings -93 307 2,255 531 -3 Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitabili		-591	-717			-612
Borrowings						0
Dividends paid -70 -114 -196 -303 -520 Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1	_					-525
Change in cash 376 192 1,083 -293 584 Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8				,		-3
Balance Sheet (RsM) Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						
Total assets 2,514 4,718 8,878 11,377 14,011 Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,885 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0		3/0	132	1,000	-233	J0 4
Cash & cash equivalent 290 471 1,554 1,261 1,845 Accounts receivable 234 575 878 1,357 1,889 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0		0.514	4.710	0.070	11 077	14.011
Accounts receivable 234 575 878 1,357 1,889 Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						
Net fixed assets 939 1,478 3,792 4,790 4,871 Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0	•					,
Total liabilities 1,004 1,704 4,047 5,121 5,806 Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						
Accounts payable 266 379 578 893 1,244 Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						
Total Debt 395 702 2,957 3,488 3,485 Shareholders' funds 1,509 3,024 4,830 6,256 8,205 Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						1,244
Profitability/Solvency Ratios (%) EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0						3,485
EBITDA margin adjusted 25.0 29.7 28.4 29.1 29.3 ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0	Shareholders' funds	1,509	3,024	4,830	6,256	8,205
ROE adjusted 33.7 31.7 28.4 31.2 34.1 ROIC adjusted 24.8 26.3 21.3 22.7 26.0	Profitability/Solvency Ratios (%)					
ROIC adjusted 24.8 26.3 21.3 22.7 26.0	EBITDA margin adjusted	25.0	29.7	28.4	29.1	29.3
						34.1
						26.0
	Net debt to equity	7.0	7.6	29.0	35.6	20.0
Total debt to capital 20.7 18.8 38.0 35.8 29.8	lotal dept to capital	20./	18.8	38.0	35.8	29.8

For further data queries on Citigroup's full coverage universe please contact CIR Data Services Asia Pacific at CitiResearchDataServices@citigroup.com or +852-2501-2791



Digesting the New Expansion Plans

In May 2007, EKC announced new expansion plans over and above the Dubai expansion (commenced production in Sep-07, capacity up from 96K to 196K CNG cyl/yr) and the new China plant (1m cyl/yr, production likely to commence in 4QFY08E). The new expansion plans are explained in detail below:

- 1. **Gandhidham expansion:** Besides the existing 340K cyl/yr plant at Gandhidham (currently running at 60%+ utilization), EKC now plans to expand this facility to produce industrial cylinders through the billet piercing route with a total capacity of 0.2m cyl/yr. The rationale is two-fold:
 - The raw materials (billets) are c.10% cheaper than seamless tubes and also readily available locally, hence reducing dependence on seamless tube imports (a major portion being sourced from Tenaris)
 - Despite higher operating costs, total cost of production is expected to be slightly lower than for cylinders manufactured through hot spinning (i.e. using tubes), hence affording EKC the flexibility to price these products competitively
- 2. Capacity for jumbo cylinders: EKC will also set up a separate line for producing 5,000 jumbo cylinders per year (large cylinders with a total weight of c.1,600kg/cyl) at the existing Gandhidham plant. While this line would initially cater to the Rs400m defence order that the company announced in Jan-07, these cylinders would also find application in transportation of gas over longer distances by gas distribution companies. City gas distribution in India is set to take off in a big way, propelled by increased supplies, improving transmission and distribution infrastructure, cost economics, and environmental benefits. Estimates have pegged the number of cities under the CGD ambit increasing to anywhere between 40 and 200 over the next 5-10 years (from 10 cities currently)¹. Since India is a relatively under-developed gas economy, use of jumbo cylinders will find particular use in transportation of gas to areas where setting up of dedicated infrastructure may be uneconomical or at best, some time away.
- 3. **New SEZ plant:** EKC also plans to set up a new greenfield plant in an SEZ in Kandla (~30km from the existing Gandhidham plant). This plant would primarily be an export-oriented unit with a capacity to produce 0.3m CNG cylinders per year from steel plates, targeted primarily at OEMs in Europe, Iran, and Pakistan. The rationale is two-fold:
 - Steel plates are cheaper than seamless tubes and also easily available from domestic manufacturers.
 - Cylinders thus produced have a lower weight to volume ratio than those produced through the traditional method, which would help EKC target OEMs that typically have a preference for such products (also possibly look at new markets like Europe), improving realizations in the process.

¹ Refer to our report titled 'India Natural Gas — Gas the Way to Go' dated 12 September 2007 for a more detailed discussion of the same. The report may be accessed at: https://www.citigroupgeo.com/pdf/SAP09180.pdf

Figure 1. EKC's new expansion plans

Type of cylinders	RM used	Location	Capacity ('000 cyl/yr)	Expected commissioning	Capex (Rs m)
Industrial cylinders Jumbo cylinders	Billets Seamless tubes	Gandhidham Gandhidham	200 5	Apr-08E Apr-08E	600
CNG cylinders	Steel plates	Kandla SEZ	300	Dec-08E	1220
Source: Company Re	ports and Citi Inve	stment Research			

Derisking the business model; moving into a different league

With these announcements, EKC would not only move into a different league globally in terms of scale, but more importantly, has addressed two key risks which have been of primary concern to us – the China market and raw material availability – as explained below.

- The expansions would enable EKC to derisk its business model by expanding its presence in geographies (esp. Middle East, Pakistan) and with customers (esp. OEMs in Middle East, Pakistan, India) it is more familiar with, relatively reducing its dependence on success of its China venture, a hitherto unexplored market that poses the highest risk to EKC, in our view.
- 2. Diversification of raw materials (billets, plates) also reduces its exposure to a single supplier (Tenaris), making it less vulnerable to the latter's pricing power, besides having a positive impact on margins.
- 3. Flexibility to price products such as industrial cylinders (produced via the billet piercing route) more competitively without compromising on margins.
- 4. Entry into new value-added segments such as jumbo cylinders where EKC is likely to have a clear competitive advantage.
- 5. The expansions would take EKC into a wholly different league and make it one of the largest global manufacturers of high pressure gas cylinders, enabling it to benefit strongly in a market marked by increasing tightness as well as entering new, lucrative markets such as Western Europe.

New target price of Rs437

- We increase our target price to Rs437 from Rs260 earlier on the back of our earnings upgrade and also as we roll forward our target multiple to Sep-09E from Dec-08E earlier.
- We base our target price on a 22x target P/E multiple (20x earlier), which is at a reasonable discount to peer multiples (in the 23-30x range, as shown in Figure 2 below). We prefer comparing EKC with capital goods companies that manufacture industrial goods and have a similar growth profile. EKC is also an indirect play on the alternate energy theme with growth driven by cost economics and environmental concerns. Despite similar earnings growth profile, we value EKC at a

discount to its peers' target multiples (vs. in line earlier) to factor in the difference in the nature of businesses and also the higher order book visibility of the capital goods companies which are direct beneficiaries of rising infrastructure capex in India.

Our target P/E is well supported by an EPS CAGR of 47% for FY07-10E and healthy capital return ratios. Although EKC is relatively small, we believe its valuations will closely track those of its peers given its exposure to the rapidly developing CNG market, for which there are only a few other plays available.

Figure 2. Peer group target price multiples

	RIC	Price	M-cap		Target	Ta	rget PE	EPS CAGR	Target	ROE
	Code	16-Nov-07	US\$m	Rating	Price	(x)	Basis	FY07-10E	P/BV^2	FY09E
Suzlon Energy	SUZL.B0	2,065	15,221	1L	2,227	26.0^{1}	Sep-09E	48.6%	9.6	36.6%
Punj Lloyd	PUJL.B0	501	3,807	1L	593	25.0^{1}	Sep-09E	55.0%	5.6	21.8%
BHEL	BHEL.B0	2,787	34,909	1L	2,542	26.0	Sep-09E	30.2%	8.5	32.7%
Larsen & Toubro	LART.B0	4,376	32,612	3L	4,010	30.0^{1}	Sep-09E	41.0%	11.7	33.7%
Thermax	THMX.B0	880	2,683	1L	764	23.0	Mar-09E	35.6%	8.2	41.4%
Average						26.8		42.1%	8.7	33.3%
Everest Kanto	EKCL.B0	312	778	1M	437	22.0	Sep-09E	47.0%	7.1	31.2%

Source: Citi Investment Research estimates. ¹Target PE on core earnings. ²Target FY09E P/BV.

On our target price, EKC would trade at a P/BV of 7.1x for FY09E, a discount to the target P/BV of the peers, despite similar return parameters, as shown in Figure 2.

Earnings upgrade drives 3-yr EPS CAGR of 47%

On our revised estimates, we now expect EKC to grow EPS at a CAGR of 47% over FY07-10E, broadly tracking sales CAGR of 48% over the same period.

The key changes to our earnings and key assumptions are summarized in Figure 3 below:

Figure 3. EKC - Key Revisions

		oroduction cylinders)		realization s/cyl)		BITDA gin (%)		EBITDA (Rs m)			EPS (Rs)	
Year to 31-Mar	Old	New	Old	New	Old	New	Old	New	% change	Old	New	% change
2008E	666	687	9,029	8,435	27.4%	28.4%	1,649	1,646	-0.2%	10.27	10.54	2.7%
2009E	988	1,034	8,590	8,657	25.9%	29.1%	2,196	2,605	18.6%	13.81	16.35	18.4%
2010E	1,257	1,411	7,952	8,834	26.7%	29.3%	2,665	3,655	37.2%	17.55	23.34	33.0%
Source: Citi Inves	tment Rese	arch estimate	es									

We adjust our FY08E earnings by 3% primarily to factor in 1HFY08 performance and slightly better than expected operating margins. We are significantly increasing our FY09-10E earnings by 18-33% on the back of the following:

- 1. Incorporation of production from the new capacities (Gandhidham billet piercing + jumbo cylinders facility to start producing in 1QFY09E, Kandla SEZ to start producing in 4QFY09E, a separate line for jumbo cylinders in the China plant to start producing in 4QFY09E). Total cylinder production in FY10E consequently increases from our earlier assumption of 1.26m to 1.41m, nearly trebling over FY07-10E.
- 2. Changes to our cost and margin assumptions are driven by:
 - Lower average raw material costs, partially mitigated by higher operating costs, for the two new plants using billets and steel plates
 - Higher margins for jumbo cylinders which are high value add products

The result is an increase in our EBITDA margin forecasts over FY08-10E from the 26-27% range earlier to 28-29% levels (average margins were 29% in 1HFY08), which we believe is attainable given the better product mix and better raw material sourcing ability and aided by the continued robust demand for the company products.

- 3. Changes to our tax rate assumptions as, besides the Dubai and China plants, the Kandla SEZ plant would also benefit from tax incentives
- 4. Incorporation of additional capex of US\$50m to be incurred over FY08-09E for the new expansions total capex assumed over the next five years equals US\$135m.

Our revised FY08-10E EPS numbers are now fully diluted for the impact of the FCCB issued (US\$35m) and the preferential allotment of shares to TVG Capital Partners (Rs800m) and CLSA (Rs87m). The total US\$57m of capital raised results in a dilution of ~8%.

Figure 4 below illustrates in detail changes to our utilization and production assumptions by plant:

Year to 31-Mar (no. of cylinders)						
•		Old			New	
	FY08E	FY09E	FY10E	FY08E	FY09E	FY10E
Aurangabad						
CNG production	-	-	-	-	-	-
Industrial production	115,500	115,500	115,500	121,000	121,000	121,000
Total production	115,500	115,500	115,500	121,000	121,000	121,000
Capacity	110,000	110,000	110,000	110,000	110,000	110,000
Capacity utilization	105.0%	105.0%	105.0%	110.0%	110.0%	110.0%
Tarapur						
CNG production	88,000	91,200	105,600	92,400	97,584	105,600
Industrial production	72,000	68,800	70,400	75,600	73,616	70,400
Total production	160,000	160,000	176,000	168,000	171,200	176,000
Capacity	160,000	160,000	160,000	160,000	160,000	160,000
Capacity utilization	100.0%	100.0%	110.0%	105.0%	107.0%	110.0%
Dubai						
CNG production	156,800	196,000	215,600	156,800	196,000	205,800
Industrial production	-	-	-	-	-	-
Total production	156,800	196,000	215,600	156,800	196,000	205,800
Capacity	196,000	196,000	196,000	196,000	196,000	196,000
Capacity utilization	80.0%	100.0%	110.0%	80.0%	100.0%	105.0%
Gandhidham						
CNG production	122,400	192,780	221,000	132,600	187,850	226,100
Industrial production	81,600	113,220	119,000	88,400	101,150	96,900
Total production	204,000	306,000	340,000	221,000	289,000	323,000
Capacity	340,000	340,000	340,000	340,000	340,000	340,000
Capacity utilization	60.0%	90.0%	100.0%	65.0%	85.0%	95.0%
Gandhidham (new - billet piercing)						
Total production (only industrial)	-	-	-	-	100,000	150,000
Capacity	-	-	-	-	200,000	200,000
Capacity utilization	-	-	-	-	50.0%	75.0%
Gandhidham (new - jumbo)						
Total production (only jumbo)	-	-	-	-	1,500	3,500
Capacity	-	-	-	-	5,000	5,000
Capacity utilization	-	-	-	-	30.0%	70.0%
Kandla (new - SEZ)						
Total production (only CNG)	-	-	-	-	15,000	180,000
Capacity	-	-	-	-	300,000	300,000
Capacity utilization	-	-	-	-	5.0%	60.0%
China						
CNG production	30,000	136,500	266,500	20,000	112,000	125,000
Industrial production	-	73,500	143,500	-	28,000	125,000
Total production	30,000	210,000	410,000	20,000	140,000	250,000
Capacity	200,000	400,000	700,000	200,000	200,000	500,000
Capacity utilization	15.0%	52.5%	58.6%	10.0%	70.0%	50.0%
China (jumbo)						
Total production (only jumbo)	-	-	-	-	500	1,500
Capacity	-	-	-	-	5,000	5,000
Capacity utilization	-	-	-	-	10.0%	30.0%
TOTAL						
CNG production	397,200	616,480	808,700	401,800	608,434	842,500
Industrial production	269,100	371,020	448,400	285,000	423,766	563,300
Jumbo production				-	2,000	5,000
Total production	666,300	987,500	1,257,100	686,800	1,034,200	1,410,800
Capacity	1,006,000	1,206,000	1,506,000	1,006,000	1,516,000	1,816,000
Capacity utilization	66.2%	81.9%	83.5%	68.3%	68.2%	77.7%
Source: Company Reports and Citi Investment Re	caarch actimates					

Summary financials

Year to 31-Mar	FY06	FY07	FY08E	FY09E	FY10E
Income					
Net sales	2,355	3,794	5,793	8,953	12,463
Products traded	-	57	-	-	-
Total operating income	2,355	3,851	5,793	8,953	12,463
Realization (Rs/cyl)	6,523	8,032	8,435	8,657	8,834
% yoy	77.9%	63.5%	50.4%	54.6%	39.2%
Expenditure					
Raw materials & goods consumed	1,306	2,282	3,119	4,865	6,619
RM cost as a % of sales	55.4%	59.3%	53.8%	54.3%	53.1%
(Increase)/decrease in inventory	(2)	(336)	(20)	(30)	(30)
Staff costs	89	144	209	293	439
% yoy	34.6%	61.2%	45.0%	40.0%	50.0%
Operating expenses	238	377	567	908	1,436
as a % of sales	10.1%	9.8%	9.8%	10.1%	11.5%
Admin, sales, & other expenses	136	240	272	313	344
otal expenditure	1,767	2,706	4,147	6,349	8,808
EBITDA	588	1,145	1,646	2,605	3,655
EBITDA margin	25.0%	29.7%	28.4%	29.1%	29.3%
nterest	37	53	102	164	198
Depreciation	98	178	248	414	530
Other income	22	40	115	108	84
Profit before tax	476	953	1,411	2,135	3,011
Provision for tax	141	236	296	406	542
Tax rate	29.6%	24.7%	21.0%	19.0%	18.0%
Profit after tax	335	718	1,115	1,729	2,469
Net income margin	14.2%	18.6%	19.2%	19.3%	19.8%
% yoy growth	134.6%	114.2%	55.4%	55.1%	42.8%

Year to 31-Mar	FY06	FY07	FY08E	FY09E	FY10E
Gross block	1,571	1,958	3,153	5,165	6,577
Less: depreciation	636	814	1,062	1,475	2,006
Net block	935	1,144	2,092	3,690	4,571
Add: CWIP	5	335	1,700	1,100	300
Net block after adjustments	939	1,478	3,792	4,790	4,871
Investments	132	134	134	134	134
Cash/bank	290	471	1,554	1,261	1,845
Net Current Assets	557	1,634	2,318	3,580	4,858
Current assets	1,152	2,636	3,398	5,192	7,161
- Inventories	423	1,144	1,747	2,700	3,759
- Receivables	234	575	878	1,357	1,889
- Loans & advances	495	917	773	1,135	1,513
Current liabilities	596	1,001	1,080	1,612	2,303
- Creditors	266	379	578	893	1,244
- Provisions	330	623	502	719	1,059
Misc exp not w/o	-	9	-	-	-
Total Assets	1,918	3,726	7,798	9,764	11,708
Share capital	176	195	202	202	202
Reserves & surplus	1,333	2,829	4,628	6,053	8,003
Total Networth	1,509	3,024	4,830	6,256	8,205
Borrowings	395	702	2,957	3,488	3,485
Long-term	307	628	793	1,104	901
Short-term	88	74	764	984	1,184
FCCB			1,400	1,400	1,400
Debt/Equity	26.2%	23.2%	61.2%	55.8%	42.5%
Debt (ex-FCCB)/Equity	26.2%	23.2%	32.2%	33.4%	25.4%
Deferred tax liability	14	0	10	20	18
Total Liabilities	1,918	3,726	7,798	9,764	11,708

Year to 31-Mar	FY06	FY07	FY08E	FY09E	FY10E
Net income	324	718	1,115	1,729	2,469
Deprec., amort.	98	178	248	414	530
Net change in WC	(122)	(1,078)	(684)	(1,262)	(1,278)
Cash from ops.	300	(182)	679	881	1,722
Capital expenditure	(591)	(717)	(2,561)	(1,412)	(612)
Cash from investing	(591)	(717)	(2,561)	(1,412)	(612)
Change in borrowings	(93)	307	2,255	531	(3)
Equity raised	844	920	887	-	-
Dividends paid	(70)	(114)	(196)	(303)	(520)
Other financing	(13)	(22)	19	10	(3)
Cash from financing	667	1,091	2,965	238	(525)
Net cash flow	376	192	1,083	(293)	584

Everest Kanto Cylinder

Company description

Everest Kanto Cylinder Limited (EKC) is the largest domestic manufacturer of high pressure gas cylinders used for the storage of industrial gases and CNG. While the first manufacturing facility (at Aurangabad) was set up in collaboration with Kanto Koatsu Yoki of Japan in 1978, the subsequent facilities have been built using in-house technology. The company currently has four manufacturing plants located in Aurangabad, Tarapur, Gandhidham, and Dubai with a total capacity to produce 806,000 cylinders per year. An aggressive expansion plan including a greenfield plant in China, expansion of the Gandhidham facility, and a new plant in an SEZ would see EKC's production capacity increase to 2.3m cylinders over the next 4-5 years.

Investment strategy

We rate the stock as Buy/Medium Risk (1M) with a target price of Rs437. We believe EKC is uniquely positioned to capture the significant growth potential of the market for high pressure gas cylinders, driven largely by increasing CNG penetration both domestically and abroad. Increased production from new and existing plants amidst the current tightness in the cylinder market would see the company deliver EPS CAGR of 47% for FY07-10 on our estimates. EKC offers a unique opportunity for investors to participate in the back-endenabling chain to service the rapidly expanding CNG market in India and overseas. While the CNG segment in India is still at a nascent stage of development vis-à-vis some other countries, cost economics, rising awareness, improving refueling infrastructure and visibility of gas supplies should see city gas distribution and consequently CNG penetration on an accelerating trajectory in India, thereby boosting demand for CNG cylinders. Coupled with the robust global outlook for natural gas-powered vehicles (population forecasted to increase to 50m by 2020, a CAGR of 17%) and a sanguine IPlinked growth outlook for industrial cylinders, we expect EKC's production to treble over FY07-10E.

Valuation

Our 12-month target price for EKC of Rs437 is based on a target P/E multiple of 22x Sep-09E earnings. Our multiple is at a reasonable discount to target multiples of its manufacturing / engineering peers which are in the 23-30x range. We base our target on mid-FY09E earnings because we believe it better captures the contribution from China, full utilization of Dubai, and part contribution from the newly announced expansions. We prefer comparing EKC with capital goods companies that manufacture industrial goods that have a similar growth profile. However, given the difference in the nature of the business and the higher order book visibility of these companies, we believe EKC should trade at a discount to its peers. EKC is also a material play on the alternate energy/CNG theme and one of the most leveraged plays to the expanding city gas distribution market in India. Our target P/E is well supported by an EPS CAGR of 47% for FY07-10E. Although EKC is relatively small, we believe its valuations will closely track those of its peers given its exposure to

the rapidly developing CNG market, for which there are only a few other plays available.

Risks


We assign a Medium Risk rating to EKC, rather than the High Risk rating as per our quantitative risk-rating system, as we think it is more appropriate given the secular nature of the business that the company operates in and the strong visibility of growth on increasing CNG penetration. The risk factor is further mitigated by the firm's low leverage and strong return parameters. Key downside risks to our target price: 1) Exposure to a single supplier – EKC's reliance on Tenaris for most of its raw material makes it vulnerable to the latter's pricing power; any unanticipated pricing action on the part of Tenaris could be a negative for EKC. However, EKC has in the past passed on cost increases to its customers. Besides, the new expansions would further mitigate this risk with EKC diversifying towards more easily available raw materials. 2) China – a hitherto unexplored market, EKC's entry there could incur teething troubles. 3) Competition – while the cylinder market in India has been relatively less exposed to competition, the low physical barriers to entry have led to some players entering the market in the recent past, which might have an adverse impact on EKC's pricing power and hamper its ability to pass on cost increases to customers. 4) Project risk – EKC is implementing significant expansion plans that are subject to time and cost over-runs that could adversely impact earnings. 5) Crude prices – significantly lower crude prices could adversely impact CNG's strong economics and consequently slow CNG penetration. If any of these risk factors has a greater impact than we anticipate, the stock might have difficulty reaching our target price.

Appendix A-1

Analyst Certification

Each research analyst(s), strategist(s) or research associate(s) responsible for the preparation and content of this research report hereby certifies that, with respect to each issuer or security that the research analyst, strategist or research associate covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) strategist(s) or research associate(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst, strategist or research associate in this research report.

IMPORTANT DISCLOSURES



Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Suzlon Energy. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Bharat Heavy, Everest Kanto Cylinder, Punj Lloyd and Suzlon Energy.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Bharat Heavy, Everest Kanto Cylinder, Larsen & Toubro and Punj Lloyd.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Bharat Heavy, Everest Kanto Cylinder, Larsen & Toubro, Punj Lloyd, Suzlon Energy and Thermax in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Bharat Heavy, Everest Kanto Cylinder, Larsen & Toubro and Punj Lloyd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Bharat Heavy, Everest Kanto Cylinder, Larsen & Toubro, Punj Lloyd, Suzlon Energy and Thermax.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Bharat Heavy, Everest Kanto Cylinder, Larsen & Toubro, Punj Lloyd, Suzlon Energy and Thermax.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution							
Data current as of 30 September 2007	Buy	Hold	Sell				
Citi Investment Research Global Fundamental Coverage (3358)	50%	38%	12%				
% of companies in each rating category that are investment banking clients	53%	55%	42%				

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Everest Kanto Cylinder (EKCL.BO)

19 November 2007

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S). Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings:

Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight the bond is expected to underper

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 16 November 2007 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Larsen & Toubro, Punj Lloyd and Suzlon Energy. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of Suzlon Energy.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission.

Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11° andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

This Product is not intended for distribution in Poland. Any receipt or review of the Product in Poland is not authorized by the Firm.

© 2007 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or

Everest Kanto Cylinder (EKCL.BO)

19 November 2007

its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST